Thalia Therapeutics Plc
THAT
Rank in Stocks
#30033
Thalia Therapeutics Plc, a specialized pharmaceutical company established in... Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Share Price
$0.00739252
Last synced: 2026-11-09
Market Cap
$6.15M
Change (1 day)
-3.78%
Change (1 year)
-9.92%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Thalia Therapeutics Plc (THAT)
Category
Healthcare
Operating Margin for Thalia Therapeutics Plc (THAT)
Operating Margin as of November 2026 TTM: -19,277.61%
According to Thalia Therapeutics Plc's latest financial reports, its current operating margin (TTM) is -19,277.61%. At the end of 2025 the company had an operating margin of -15,199.56%.
Operating Margin history for Thalia Therapeutics Plc from 2025 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -19,277.61% | 26.83% |
| 2025 | -15,199.56% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -99.99% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Thalia Therapeutics Plc's operating margin
What is Thalia Therapeutics Plc's operating margin?
Thalia Therapeutics Plc's operating margin is -19,277.61%, as of Nov 2026.
How does Thalia Therapeutics Plc's operating margin compare with similar companies?
Thalia Therapeutics Plc's operating margin (-19,277.61%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.